

168304

THE EFFECT OF MOLECULAR WEIGHT AND DIFFERENT DEGREE OF DEACETYLATION OF CHITOSAN ON THE IN VITRO AND IN VIVO RELEASE OF ORAL INSULIN PREPARATIONS

By

Qutuba G. Hessen

Petra University Library



91194

A thesis submitted in
Partial fulfillment of the
Requirements for the Degree of
Master of Science
In Pharmaceutical Sciences

at

Petra University
Faculty of pharmacy
Amman-Jordan

University of Petra Library	
Accession Number :	91194
Date :	615.365
Classification Number :	H.587

TV

December 2009

**THE EFFECT OF MOLECULAR WEIGHT
AND DIFFERENT DEGREE OF DEACETYLATION OF
CHITOSAN ON THE IN VITRO AND IN VIVO RELEASE OF
ORAL INSULIN PREPARATIONS**

By

Qutuba G. Hessen


**A thesis submitted in Partial fulfillment of the Requirements for the
Degree
of
Master of Science
In Pharmaceutical Sciences
at
Petra University
Faculty of pharmacy
Amman-Jordan
December 2009**

Supervisor

Name

Prof. Tawfik Alhussainy


Signature



Co-supervisor

Name

Dr. Nidal Qinna



Examiantion Committee

Name


Prof. Tawfik Alhussainy

Dr. Nidal Qinna

Prof. Tawfiq Arafat

Dr. Majid Feddah

Prof. Khalid Aiedeh



Abstract

The Effect of Different Molecular Weight and Degree of Deacetylation of Chitosan On The In vitro and In vivo Release of Oral Insulin Preparation

By

Qutuba G. Hessen

There are many barriers to delivering insulin perorally. One of the major obstacles is the harsh environment of the GIT that cause destruction of insulin. The hydrophilicity and high molecular weight of insulin represented other obstacle for its permeability across the intestinal mucosa. There are many ongoing investigations to improve the oral bioavailability of peptide and protein formulations. Chitosan has been shown to be potential in delivering oral and other mucosally administered proteins due to its excellent mucoadhesive and permeation enhancing effects across the biological surfaces. Previous studies have demonstrated the possibility of formulating an oral insulin delivery system by combining the advantages of nanoencapsulation and the use of oily vehicle. These studies revealed a necessity to well understanding the effect of molecular weight and degree of deacetylation on the formulated system. Thus, different molecular weights (1.3, 6, 13, 18, 30 kDa) and degrees of deacetylation (100, 80, 75, 65, 55 DDA%) were prepared and characterized.

In vitro studies revealed that the low molecular weight chitosan, compared to high molecular weight chitosan, had pronounced increment in its solubility due to the shortage in length of chitosan chains. This shortening of chitosan chains had its impact towards reducing the size of the formulated nanoparticles. On the other hand, and in relation to changing DDA%, the executed in silico studies explained that the flexibility of chitosan chains was increased as the DDA% decreased. At this point of

flexibility, the chitosan chains had the ability to wrapping on the insulin molecule and applying its construction power to reduce the particle size of the PEC to the nano-scale

In vivo results, using STZ diabetic rat model, demonstrated that low molecular weights of chitosan significantly enhanced the hypoglycemic effect of oral insulin. In addition; each molecular weight of chitosan had its optimum DDA%. At this DDA%, it was thought that chitosan had the best conformation to form the smallest particle size when compared to other DDA% of the same molecular weight. As a result, the lowest used molecular weight (1.3 kDa / 80%DDA) revealed to possess the best insulin release compared to the other investigated higher molecular weights.

In conclusion, the current study exposed the importance of optimizing the molecular weight of chitosan in relation with its DDA% in oral insulin delivery formulation.

Acknowledgements

It is difficult to acknowledge everyone who has helped me over the last two years in my graduate work. The work was difficult and I would not have done it without support and help.

First and foremost, I would like to thank my advisor Prof. Tawfiq Al-hussainy, who I owe a great deal of thanks to him. His guidance has helped me gain an expertise in the pharmacology field. I am eternally grateful for everything he has taught me. Many thanks go to Dr. Nidal Qinna made me realize the value of continuing my education and in the process I have learned much more than just my subject; I have learned the value of continued excellence, education, and personal skill development throughout my work with you. He was always a staunch supporter of mine and continued to encourage me throughout my study.

I wish to pay my respect and express my thanks to Dr. Adnan Badwan for his invaluable support, extracurricular discussions and useful suggestions throughout this research work. Additionally, special thanks go to the family of The Jordanian Pharmaceutical Manufacturing Company (JPM) for all the effort and support throughout this study. A special thanks to Eng. Nawzat Al-Jbour, who was much more than just a labmate. Our friendship can never be replaced and will never be forgotten. I want to express my deep appreciation to Dr. Mayyas Remawi for his encouragement and supervision throughout the course of this work. I must thank my friend Dr. Joumaa Kafawein for his assistance and using his centrifugation instrument.

I would like to thank my committee members: Prof. Tawfiq Al-hussainy, Dr. Nidal Qinna, Prof. Tawfiq Arafat, Dr. Majid Feddah, Prof. Khalid Aiedeh. They have been invaluable mentors in my master progress. They have also been trust advisors with me in my personal endeavors and future career plans. I value their support and counsel and hope to be able to continue our relationship for many years.

My friends, Mohammad Albayed, Abdulla Al-Safi and Obbei Asem, I would like to thank you for helping me keeping my sanity during my M.Sc. I am forever grateful for their love and support both before and during my graduate studies.

This thesis was only possible due to the help I received from my family who deserve a great deal of thanks for all the help and support they have given to me. I wish to thank my parents, Dr. Ghanem Al-Qaissi and Dr. Salwa Al-Kinani, my brother, Yehya Al-Qaissi, and my sister, Reem Al-Qaissi, who instilled in me perseverance and faith in my abilities. They were able to extent a helping hand to me for supporting and mentorship in the pivotal moments in my study and for that I am truly grateful.

Table of Contents

1. INTRODUCTION	2
1.1. ORAL DELIVERY OF PROTEIN	2
1.2. INSULIN AND INSULIN THERAPY	3
1.3. DIABETES MELLITUS	5
1.4. ALTERNATIVE ROUTES OF INSULIN ADMINISTRATION	6
1.5. STRATEGIES FOR ORAL DELIVERY OF INSULIN	9
1.6. NANOTECHNOLOGY AND NANOPARTICLE	11
1.7. CHITOSAN	12
1.8. PROPERTIES OF CHITOSAN	15
1.9. LOW MOLECULAR WEIGHT CHITOSAN (LMWC)	20
1.10. DEGREE OF DEACETYLATION (DDA%)	22
1.11. METHODS OF PREPARATION OF CHITOSAN NANOPARTICLES	22
1.12. METHOD OF NANOPARTICLES FORMULATION	24
1.13. AIM AND SCOPE	28
2. MATERIALS AND METHODS	31
2.1 MATERIALS AND INSTRUMENTS	31
2.1.1. CHEMICALS	31
2.1.2. INSTRUMENTS	32
2.2. METHODS	32
2.2.1. PREPARATION OF LOW MOLECULAR WEIGHT OLIGOCHITOSAN (LMWC)	32
2.2.2. PREPARATION OF LMWC WITH DIFFERENT DEGREES OF DEACETYLATION	33
2.3. CHARACTERIZATION OF PRODUCED GRADES OF CHITOSAN	35
2.3.1. DETERMINATION OF VISCOSITY AVERAGE MOLECULAR WEIGHT (M.W.)	35
2.3.2. DETERMINATION OF THE DEGREE OF DEACETYLATION (DDA)	36
2.3.3. FT-IR SPECTROMETRY	38
2.3.4. ¹ H-NMR SPECTROMETRY	38
2.3.5. DIFFERENTIAL SCANNING CALORIMETRY (DSC)	38
2.3.6. SURFACE MORPHOLOGY	39
2.3.7. MOLECULAR MODELING (MM)	39
2.4. PREPARATION AND CHARACTERIZATION OF INSULIN-CHITOSAN POLYELECTROLYTE COMPLEX (PEC) AQUEOUS PHASE	40

2.5. PREDICTION OF NUMBER OF IONIZED AMINE GROUPS FOR EACH CHITOSAN GRADES AT PH (6.25)-----	41
2.6. PREPARATION AND CHARACTERIZATION OF THE DISPERSION PHASE-----	42
2.7. PREPARATION AND CHARACTERIZATION OF THE NANOPARTICLES DISPERSION SYSTEM-----	42
2.8. IN VIVO STUDIES ON STREPTOZOTOCIN (STZ) DIABETIC RATS-----	43
2.8.1. ANIMALS-----	43
2.8.2. INDUCTION OF DIABETES USING STZ -----	43
2.8.3. PHARMACOLOGICAL ACTIVITY EVALUATION OF INSULIN-LOADED DISPERSION -----	44
3. RESULTS AND DISCUSSION -----	47
3.1. DETERMINATION OF AVERAGE MOLECULAR WEIGHT (M.W.)-----	47
3.2. DETERMINATION OF DEGREE OF DEACETYLATION -----	49
3.3. FT-IR SPECTROMETRY -----	50
3.4. ¹ H-NMR SPECTROMETRY -----	58
3.5. DIFFERENTIAL SCANNING CALORIMETRY (DSC) -----	66
3.6. SURFACE MORPHOLOGY -----	72
3.7. MOLECULAR MODELING -----	76
3.8. PARTICLE SIZE DETERMINATIONS -----	80
3.9. THE OPTIMUM NUMBER OF NH ₃ ⁺ FOR EACH CHITOSAN GRADES-----	86
3.10. PHARMACOLOGICAL ACTIVITY OF INSULIN-LOADED NANOPARTICLES -----	90
4. CONCLUSION -----	99
5. REFERENCES -----	104

List of Figures

Figure 1.1: Insulin molecular structure -----	4
Figure 1.2: Gastrointestinal Barriers for oral delivery of proteins -----	9
Figure 1.3: Skeleton structure of glucosamine unit -----	12
Figure 1.4: Mucoadhesive mechanism of chitosan -----	18
Figure 1.5: Permeability enhancing properties of chitosan -----	20
Figure 1.6: The preparation steps of w/o insulin microemulsion as oral delivery system -----	26
Figure 3.1: Calibration curve of N-acetylglucosamine standard -----	49
Figure 3.2: IR spectra for different grades of fully deacetylated chitosan over the frequency range 4000-600 cm⁻¹ -----	52
Figure 3.3: IR spectra for chitosan 30kDa with different DDA%, A=55%, B=80%, C=100% over the frequency range 4000-400 cm⁻¹ -----	53
Figure 3.4: IR spectra for chitosan 18kDa with different DDA%, A=55%, B=80%, C=100% over the frequency range 4000-400 cm⁻¹ -----	54
Figure 3.5: IR spectra for chitosan 13kDa with different DDA%, A=55%, B=80%, C=100% over the frequency range 4000-400 cm⁻¹ -----	55
Figure 3.6: IR spectra for chitosan 6kDa with different DDA%, A=55%, B=80%, C=100% over the frequency range 4000-400 cm⁻¹ -----	56
Figure 3.7: IR spectra for chitosan 1.3kDa with different DDA%, A=55%, B=80%, C=100% over the frequency range 4000-400 cm⁻¹ -----	57
Figure 3.8: ¹H_NMR spectra of (a) Acetylated chitosan (b) Fully deacetylated chitosan -----	58
Figure 3.9: ¹H-NMR spectra for chitosan 30kDa. with different degrees of deacetylation -----	60

Figure 3.10: ¹H-NMR spectra for chitosan 18kDa. with different degrees of deacetylation -----	61
Figure 3.11: ¹H-NMR spectra for chitosan 13kDa. with different degrees of deacetylation -----	62
Figure 3.12: ¹H-NMR spectra for chitosan 6kDa. with different degrees of deacetylation -----	63
Figure 3.13: ¹H-NMR spectra for chitosan 1.3kDa. with different degrees of deacetylation -----	64
Figure 3.14: DSC diagrams of chitosan 30kDa. with different degrees of deacetylation, where A=100%DDA; B=80%DDA and C=55%DDA -----	67
Figure 3.15: DSC diagrams of chitosan 18kDa. with different degrees of deacetylation, where A=100%DDA; B=80%DDA and C=55%DDA -----	68
Figure 3.16: DSC diagrams of chitosan 13kDa. with different degrees of deacetylation, where A=100%DDA; B=80%DDA; C=75%DDA; D=65%DDA and E=55%DDA -----	69
Figure 3.17: DSC diagrams of chitosan 6kDa. with different degrees of deacetylation, where A=100%DDA; B=80%DDA and C=55%DDA -----	70
Figure 3.18: DSC diagrams of chitosan 6kDa. with different degrees of deacetylation, where A=100%DDA; B=80%DDA and C=55%DDA -----	71
Figure 3.19: Photographs of chitosan different molecular weight (MW) (kDa) and degree of deacetylation (DDA) (%) prepared by evaporation of an aqueous solution (1 gram/50 ml) at 40 oC for 24 hrs -----	73
Figure 3.20: Scanning Electron Microscopic (SEM) photographs of chitosan with different molecular weight (M.W.) and degree of deacetylation (DDA%) with a magnification of 4000X -----	75
Figure 3.21: Molecular Modeling for Type I, chitosan 10kDa-100%DDA ---	77
Figure 3.22: Molecular Modeling for Type II, chitosan 10kDa-80%DDA ---	78
Figure 3.23: Molecular Modeling for Type III, chitosan 10kDa-55%DDA ---	79

Figure 3.24: Aggregation size of insulin-chitosan 18kDa. with different degrees of deacetylation loaded in SCOS-Oleic acid mixture -----	82
Figure 3.25: Aggregation size of insulin-chitosan 13kDa. with different degrees of deacetylation loaded in SCOS-Oleic acid mixture -----	83
Figure 3.26: Aggregation size of insulin-chitosan 6kDa. with different degrees of deacetylation loaded in SCOS-Oleic acid mixture -----	84
Figure 3.27: Aggregation size of insulin-chitosan 1.3kDa. with different degrees of deacetylation loaded in SCOS-Oleic acid mixture -----	85
Figure 3.28: Percent decrease in glucose level of STZ diabetic rats given oral insulin preparations containing chitosan M.W. 13 kDa / 65%DDA in two different doses (50 U/kg) and (25 U/kg) and SC insulin (1 U/kg) -----	93
Figure 3.29: Percent decrease in glucose level of STZ diabetic rats given oral insulin preparations containing chitosan M.W. 18 kDa (50 U/kg) with degrees of deacetylation 55%, 80% and 100% and SC insulin (1 U/kg) compared to a placebo group-----	94
Figure 3.30: Percent decrease in glucose level of STZ diabetic rats given oral insulin preparations containing chitosan M.W. 13 kDa (50 U/kg) with degrees of deacetylation 55%, 80% and 100% and SC insulin (1 U/kg) compared to a placebo group-----	95
Figure 3.31: Percent decrease in glucose level of STZ diabetic rats given oral insulin preparations containing chitosan M.W. 1.3 kDa (50 U/kg) with degrees of deacetylation 55%, 80% and 100% and SC insulin (1 U/kg) compared to a placebo group-----	96
Figure 3.32: Percent decrease in glucose level of STZ diabetic rats given oral insulin preparations containing chitosan 1.3 kDa/ 80%DDA; 13 kDa/ 80%DDA and 18 kDa/ 60%DDA (50 U/kg) and SC insulin (1 U/kg) compared to a placebo group-----	97

List of Tables

Table 2-1: The optimum procedure and conditions to produce different degrees of deacetylation of chitosan-----	34
Table 3-1: The average molecular weight of chitosan produced by acid hydrolysis within different time intervals, calculated using Mark-Houwink Equation-----	48
Table 3-2: ¹ H-NMR characterization results of the prepared grades of chitosan -----	65
Table 3-3: The predicted number of (NH ₃ ⁺) available in different wt% of polyelectrolyte complex solution using different grades of chitosan added to 2gm of 20wt% SCOS in oleic acid and their effect on dispersion aggregate diameter, at 25oC-----	89

Abbreviation

DDA%	Degree of Deacetylation
Cs	Chitosan
STZ	Streptozotocin
Labrasol®	PEG-8 caprylic/capric glycerides
Plurol®	polyglyceryl-6 dioleate
IR	Infrared Spectroscopy
DSC	Differential Scanning Calorimetry
NMR	Proton Nuclear Magnetic Resonance
M.W.	Molecular Weight
min.	Minute
r.p.m.	Rotating per minute
MP	megapixel
gm	Gram
mg	Milligram
nm	Nanometer
RSD	Relative standard deviation
S.C.	Subcutaneous injection
kg	Kilogram
μmole	Micromole
M	Molarity
SEM	Scanning Electron Microscope
km	Molar ratio

Chapter One

Introduction

1. Introduction

The emerging technique of combinatorial chemistry, along with a growing knowledge of biochemistry of human body, has lead to an ever-increasing number of therapeutic proteins in the treatment of diseases. However, these proteins often lack durability that more traditional small molecule pharmaceuticals possess. Where simple therapeutic agent, such as Aspirin, can be taken orally and reach the blood stream intact, the lager or more delicate protein must often be delivered directly into the bloodstream through injection. In the case of insulin, less than 0.1% of the orally dosed insulin reaches the bloodstream intact (Banting F. & Best H., 1998).

1.1. Oral delivery of protein


The oral delivery of therapeutic proteins has often been referred to as the 'Holy Grail' of drug delivery (Peppas N.A. *et al.*, 2004). Therapeutic proteins that are characterized by poor permeability across mucosal membranes commonly possess one or more of the following physicochemical characteristics: low octanol /water partitioning, presence of charged or hydrogen-bonding functional groups, and high polar surface area (Chornet E. & Dumitriu S., 1998a). However, therapeutic proteins are most frequently delivered by injection because of their large molecular weight (>3500 Da.), their hydrophilicity that prevent them to cross the lipophilic barrier of mucosal walls and the sensitive three-dimensional structure required for proteins to remain biologically active (Peppas N.A. *et*

al., 2004). Oral protein delivery is an ideal therapy because it would increase patient compliance and comfort over injection, better mimic physiologic delivery of proteins, provides a simple means of administration, reduce costs, and potentially improve the efficacy of a therapeutic treatment. Although oral protein delivery could be beneficial for many individuals, there are two key challenges to making it a successful therapy: (1) maintaining the functionality of the protein and (2) increasing the bioavailability of the drug.

Insulin, calcitonin, heparin, erythropoietin, interferon, and human growth hormone are just a few examples of therapeutic proteins actively being investigated as candidates for oral delivery. While all of those proteins are important for treating various diseases and illnesses, the focus of this research was using insulin as a model protein for oral delivery.

1.2. Insulin and insulin therapy

Insulin is a protein composed of two polypeptide chains (5800Da.) which are covalently bound by disulfide bonds between cysteine residues (Jintapattanakit A. *et al.*, 2007a) as show in (Figure 1.1) . Insulin is secreted by β -cells of pancreatic islets in response to high blood glucose levels. Insulin is a hormone, which is necessary for glucose uptake in skeletal muscle and adipose tissue, and it also stimulates the formation of glycogen from glucose in the liver. In addition, insulin inhibits gluconeogenesis, thus slowing the hepatic glucose uptake. In contrast to insulin, glucagon is a hormone secreted by the α -cells of the pancreatic islets in response to low blood sugar. Glucagon induces the liver to secrete glucose by breaking down glycogen, thus raising the blood sugar level (Ross S.A. *et al.*, 2004).



Insulin monomer



insulin dimer



insulin hexamer

Figure 1.1: Insulin molecular structure

1.3. Diabetes Mellitus

Diabetes Mellitus (DM) is a debilitating disease that is defined as the presence of high blood glucose levels due to either deficiencies in insulin production, insulin action, or both. There are approximately 150 million cases of diabetes mellitus in worldwide (Armour T.A. *et al.*, 2005). The increased glucose level can cause irreversible damage to the patient. Complications of the disease can include retinopathy, nephropathy, neuropathy, heart diseases and even death (Abolfotouh M.A., 1999).

More specifically, *Type 1 Diabetes Mellitus* (or insulin dependent diabetes mellitus, IDDM) is classified as an autoimmune destruction of the pancreatic β cells, or the insulin-producing cells of the body. The exact cause of the disease is unknown, but it thought to be induced by both genetic and environmental factors. Type 1 Diabetes is called Juvenile Diabetes as the onset of it begins in childhood (Hammami M.M., 1997a; Salsali A. & Nathan M., 2006a). *Type 2 Diabetes Mellitus* (or non-insulin dependent diabetes mellitus, NIDDM) is diagnosed when a patient begins to become resistant to insulin production and the patient may even eventually lose the ability to produce insulin. Age, obesity, family history of diabetes, race/ethnicity, and inactivity are all factors that make certain individuals more prone to developing type 2 diabetes (Yap W.S. *et al.*, 1998; Salsali A. & Nathan M., 2006b). *Gestational Diabetes (GDM)* is defined as any abnormality in glucose levels noted for the first time during pregnancy. During pregnancy, the placenta and placental hormones create an insulin resistance that is most pronounced in the last trimester. Risk assessment for diabetes is suggested starting at the first prenatal visit. High-risk individuals should be screened immediately.